Zobrazeno 1 - 10
of 156
pro vyhledávání: '"Nelson L. Michael"'
Autor:
Peter B. Gilbert, Shida Shangguan, Fabrice Bailleux, Sanjay Gurunathan, Michal Juraska, Aviva Geretz, Christopher Bryant, Zoe Moodie, Shuying Sue Li, Kriengsak Limkittikul, Danaya Chansinghakul, Philip K. Ehrenberg, Wut Dulyachai, Richard G. Jarman, Nelson L. Michael, Alain Bouckenooghe, Carina Frago, Rasmi Thomas, Arunee Sabchareon, Weerawan Hattasingh
Publikováno v:
Human Immunology. 83:53-60
The recombinant, live, attenuated, tetravalent dengue vaccine CYD-TDV has shown efficacy against all four dengue serotypes. In this exploratory study (CYD59, NCT02827162), we evaluated potential associations of host human leukocyte antigen (HLA) alle
Autor:
Peter D. Kwong, Misook Choe, Bonnie M. Slike, M. Gordon Joyce, Samantha M. Townsley, Elizabeth J. Martinez, Tongqing Zhou, Lindsay Wieczorek, Morgane Rolland, Kayvon Modjarrad, Dominic Paquin-Proulx, Vincent Dussupt, Weam I. Zaky, Nelson L. Michael, Magdalena Rutkowska, Isabella Swafford, Benjamin J. Doranz, Shelly J. Krebs, Theodora Hatziioannou, Gregory D. Gromowski, Ningbo Jian, Caroline E. Peterson, Phyllis A. Rees, Clayton Smith, Michelle Zemil, Paul D. Bieniasz, Kerri G. Lal, Victoria R. Polonis, I-Ting Teng, Gina Donofrio, William W. Reiley, Wei-Hung Chen, Christopher N. Selverian, Rajeshwer S. Sankhala, Jeffrey R. Currier, Aslaa Ahmed, Letzibeth Mendez-Rivera, Ursula Tran, Nathaniel D. Jackson, Agnes Hajduczki, Paul V. Thomas, Sarah R. Tritsch, William C. Chang, Fabian Schmidt, Edgar Davidson, Christopher N. Mores
Publikováno v:
Nature Immunology
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus s
Autor:
Sandrine Soman, Shelly J. Krebs, Diane L. Bolton, Gregory D. Gromowski, Ines Lakhal-Naouar, Swagata Kar, Michelle Zemil, Linda L. Jagodzinski, Amy R. Henry, Robert A. Seder, Lindsay Wieczorek, Hannah Grove, Dominic Paquin-Proulx, Adrienne Winn, Daniel C. Douek, Holly R. Hack, Caitlin Kuklis, Kamil Radzyminski, Rafael De La Barrera, Matthew Gagne, Caroline E. Peterson, James F. Wood, Heather Hernandez, Alexander R. A. Anderson, Xiankun Zeng, Stasya Zarling, Wei-Hung Chen, Mark G. Lewis, Rajeshwer S. Sankhala, Prakriti Mudvari, Andrew Pekosz, Victoria R. Polonis, Maciel Porto, Mangala Rao, Paul V. Thomas, Eli Boritz, M. Gordon Joyce, Sheila A. Peel, Elham Bayat Mokhtari, Kathryn McGuckin Wuertz, Nelson L. Michael, Sharon P. Daye, Akshaya Ganesh, Agnes Hajduczki, Gary R. Matyas, Jeffrey W. Froude, Vincent Dussupt, Erica K. Barkei, Kayvon Modjarrad, Jeffrey R. Currier, Sandhya Vasan, Janice Darden, Isabella Swafford, Elizabeth J. Martinez, Mehul S. Suthar, Ming Dong
Publikováno v:
npj Vaccines, Vol 6, Iss 1, Pp 1-11 (2021)
NPJ Vaccines
NPJ Vaccines
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferre
Autor:
Caroline Subra, Natalie D. Collins, Christian Hofer, Jinyan Liu, Elyse Teow, Noe B. Mercado, Victoria M. Giffin, Laurent Pessaint, Hanne Andersen, Erica K. Barkei, Tochi Anioke, Jingyou Yu, Hannah A.D. King, Donald S. Burke, Dan H. Barouch, Anthony L. Cook, Julia Barrett, Kayvon Modjarrad, Diane Bolton, Katherine McMahan, David L. Hope, Jason Velasco, Huahua Wan, Sarah Gardner, Daniel Sellers, Nelson L. Michael, Alex Van Ry, Mark G. Lewis, Felix Nampanya, Abishek Chandrashekar, Aiquan Chang
Publikováno v:
Journal of virology. 96(2)
Live oral vaccines have been explored for their protective efficacy against respiratory viruses, particularly for adenovirus serotypes 4 and 7. The potential of a live oral vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
Autor:
Agustin Bueso, John J. Treanor, Maria Angeles Ceregido, Shelly Ramirez, Aiying Chen, Matthew Bonaparte, Saranya Sridhar, David Diemert, Helene Janosczyk, Sonal S. Munsiff, Guy de Bruyn, Ya Meng, Marie-Helene Grillet, Catherine Moreau, Onyema Ogbuagu, Roger Masotti, Marguerite Koutsoukos, Fernanda Tavares-Da-Silva, Carlos A. DiazGranados, Denise Lopez, Doris M Rivera M, Brandon Essink, Stephen R. Walsh, Jiayuan Shi, Anne-Laure Chabanon, Nicole Grunenberg, Richard Canter, Vanessa Raabe, Ansoyta Said, Dalia von Barbier, Joaquin Arnel, Enrique Rivas, Bo Fu, Lode Schuerman, Nadine Rouphael, Natalya Romanyak, Michael C. Keefer, Maryam Keshtkar-Jahromi, Lawrence D Sher, Sandra Mendoza, Nelson L. Michael, Judith M. White, Tina Tong, Roman Chicz, Randall Severance, Stephen Savarino
SummaryBackgroundThis study evaluated the safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein candidate vaccine, CoV2 preS dTM.MethodsThis Phase 2, modified double-blind, parallel-group study (NCT04762680) was conducted in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3fce641823840889866445ce873de41d
https://doi.org/10.1101/2021.10.08.21264302
https://doi.org/10.1101/2021.10.08.21264302
Autor:
Morgane Rolland, Julie A Ake, Eric Sanders-Buell, Sorachai Nitayaphan, Sandhya Vasan, Punnee Pitisuttithum, Sodsai Tovanabutra, Anne Marie O'Sullivan, Nelson L. Michael, Yifan Li, Leigh Anne Eller, Merlin L. Robb, Shelly J. Krebs, Gina Donofrio, Supachai Rerks-Ngarm, Lucas Maganga, Samantha M. Townsley, Meera Bose, Hannah Kibuuka, Josphat Kosgei, Hongjun Bai, Vincent Dussupt
Publikováno v:
Journal of Virology
Identifying whether viral features present in acute HIV-1 infection predetermine the development of neutralization breadth is critical to vaccine design. Incorporating such features in vaccine antigens could initiate cross-reactive antibody responses
Autor:
Chris Beyrer, Myron S. Cohen, Lawrence Corey, Nelson L. Michael, Trevor Bedford, Morgane Rolland
Publikováno v:
N Engl J Med
SARS-CoV-2 and Immunosuppression In this article, the authors discuss the challenges of SARS-CoV-2 infection in patients with a weakened immune system, including the potential implications regardin...
Autor:
Kathryn McGuckin Wuertz, Matthew Gagne, Sharon P. Daye, Gary R. Matyas, Erica K. Barkei, Swagata Kar, Rafael De La Barrera, Caroline E. Peterson, Elyham Bayat Mokhtari, Michelle Zemil, Linda L. Jagodzinski, Elizabeth J. Martinez, Sandrine Soman, Mehul S. Suthar, Wei-Hung Chen, M. Gordon Joyce, Sheila A. Peel, Dominic Paquin-Proulx, Heather Hernandez, Rajeshwer S. Sankhala, Sandhya Vasan, Stasya Zarling, Caitlin Kuklis, Janice Darden, Andrew Pekosz, Diane L. Bolton, Ming Dong, Mark G. Lewis, Xiankun Zeng, Paul V. Thomas, Victoria R. Polonis, James F. Wood, Marciel Porto, Prakriti Mudvari, Ines Elakhal Naouar, Daniel C. Douek, Shelly J. Krebs, Holly R. Hack, Mangala Rao, Eli Boritz, Gregory D. Gromowski, Kamil Radzyminski, Robert A. Seder, Alexander R. A. Anderson, Akshaya Ganesh, Hannah Grove, Isabella Swafford, Amy R. Henry, Adrienne Winn, Agnes Hajduczki, Nelson L. Michael, Kayvon Modjarrad, Jeffrey W. Froude, Lindsey Wieczorek, Vincent Dussupt, Jeffrey R. Currier
Publikováno v:
bioRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. We evaluated whether a spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60f22541b3a4b216dde47acf2f8f3ef8
https://doi.org/10.1101/2021.06.16.448525
https://doi.org/10.1101/2021.06.16.448525
Autor:
John D. Ventura, Abishek Chandrashekar, Peter Abbink, Noe B. Mercado, Rafael De La Barrera, Kenneth H. Eckels, Nelson L. Michael, Erica N. Borducchi, Michael P. Busch, Zhenfeng Li, Dan H. Barouch, Kayvon Modjarrad, Rafael A. Larocca
Publikováno v:
PLoS Pathogens, Vol 17, Iss 6, p e1009673 (2021)
PLoS Pathogens
PLoS Pathogens
Pre-existing immunity to flaviviruses can influence the outcome of subsequent flavivirus infections. Therefore, it is critical to determine whether baseline DENV immunity may influence subsequent ZIKV infection and the protective efficacy of ZIKV vac
Autor:
Matthew A. Cole, Sebastian Molnar, Michelle Zemil, Tricia J. Lang, Jiae Kim, Misook Choe, Joshua M. Carmen, Clayton Smith, Elizabeth J. Martinez, Morgane Rolland, Patrick M. McTamney, Debra K. Duso, Wei-Hung Chen, Zuzana Villar, William W. Reiley, Therese Oertel, Nelson L. Michael, Rajeshwer S. Sankhala, Gary R. Matyas, Neelakshi Gohain, Christopher P. Karch, Connor Whalen, Mark T. Esser, Val Nd, Shelly J. Krebs, Elaine B. Morrison, Htet Khanh, Victoria R. Polonis, Alexander R. A. Anderson, Michael Gordon Joyce, Saravanan Rajan, Caroline E. Peterson, Dussupt, Ursula Tran, Weimin Wu, James Brett Case, Aslaa Ahmed, Chandrika B. Kannadka, Shikha Shrivastava, Ousman Jobe, Akshaya Ganesh, Shania E. Muncil, Michael S. Diamond, Lindsay Wieczorek, Agnes Hajduczki, Caitlin Kuklis, Letzibeth Mendez-Rivera, Yifan Li, Kayvon Modjarrad, Paul V. Thomas, William C. Chang, Gregory D. Gromowski, Larry W. Kummer, Sandrine Soman, Rita E. Chen, Mangala Rao, Zoltan Beck, Lorean Rosado, David McCurdy, Currier
Publikováno v:
Cell Reports
bioRxiv
article-version (status) pre
article-version (number) 1
bioRxiv
article-version (status) pre
article-version (number) 1
The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize fou